The MS Drug That Doesn't Kill Your Immune Cells (It Just Calms Them Down)
Novartis's remibrutinib just beat an older MS drug in two large Phase 3 trials, but the real story is *how* it works. Unlike treatments that destroy or trap immune cells, this BTK inhibitor simply tells them to stand down. And in a competitive race littered with safety failures, that distinction could be worth billions.
A New Trick for an Old Problem
Multiple sclerosis treatments have always come with an uncomfortable trade-off. You want to stop the immune system from attacking the brain. But most drugs do that by either wiping out immune cells or trapping them in your lymph nodes, which leaves patients more vulnerable to infections and other problems. It's like trying to stop a bar fight by kicking everyone out of the building. Effective, sure, but now the bar is empty.
Novartis just showed there might be a better way. Its oral drug remibrutinib beat an older MS treatment in two large Phase 3 trials, cutting relapses significantly while keeping its safety profile clean. And it does something fundamentally different from the drugs patients take today: instead of destroying or corralling immune cells, it just tells them to chill out.
What the Trials Actually Showed
The results come from REMODEL-1 and REMODEL-2, two Phase 3 trials that enrolled roughly 2,000 adults with relapsing multiple sclerosis. The comparator was teriflunomide (brand name Aubagio), a well-established oral MS drug that's been around for over a decade.
Remibrutinib hit the primary endpoint in both trials: a significantly lower annualized relapse rate than teriflunomide. It also beat the older drug on key secondary measures, including reductions in inflammatory brain lesions visible on MRI scans. Perhaps most importantly for patients, the pooled data showed a clinically meaningful delay in disability progression, with a particularly encouraging signal at the six-month mark.
On the safety side, Novartis reported no liver toxicity signal and no cases of Hy's Law (a marker for serious drug-induced liver injury). That detail matters more than you might think, and we'll get to why in a moment.
The Bouncer vs. the Therapist
To understand why remibrutinib is generating so much excitement, you need to understand how it's different from the drugs already on the market.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
MS happens when the immune system, specifically B cells and other inflammatory cells, attacks the protective coating around nerve fibers in the brain and spinal cord. Current treatments take two main approaches. Anti-CD20 therapies (like Roche's ocrelizumab) work by depleting B cells from the bloodstream entirely. S1P modulators (like Novartis's own fingolimod) trap immune cells in lymph nodes so they can't reach the brain. Both strategies reduce relapses, but they come with trade-offs: fewer immune cells means higher infection risk and other complications over years of treatment.
Remibrutinib takes a completely different approach. It's a BTK inhibitor, which means it blocks an enzyme called Bruton's tyrosine kinase inside immune cells. Think of it as the difference between firing an employee and just revoking their access badge. The B cells stick around, but they lose their ability to cause trouble. They can't activate properly, can't release inflammatory signals, and can't present the molecular "wanted posters" that direct attacks against nerve tissue.
There's a bonus, too. BTK isn't just active in B cells; it also operates in microglia, the brain's own resident immune cells. That means remibrutinib may be able to calm inflammation both in the bloodstream and inside the central nervous system. Existing therapies mostly work only on the peripheral side of that equation.
The Race With a Body Count
Novartis isn't alone in chasing BTK inhibition for MS. Three other companies have been running hard at this target, and the results so far tell a cautionary tale.
Merck KGaA's evobrutinib was the first to stumble. It failed its Phase 3 trials back in 2023, missing the primary relapse endpoint entirely. That knocked Merck out of serious commercial contention and left the field wondering whether BTK inhibitors would work at all in MS.
Sanofi's tolebrutinib has fared better on efficacy but worse on safety. Its Phase 3 program generated mixed results: the progressive MS trial (called PERSEUS) didn't show significant benefit over placebo, and the drug ran into serious hepatic safety concerns, including regulatory pushback in the U.S. over liver toxicity risk. For a drug patients might take for decades, liver problems are a dealbreaker.
Roche's fenebrutinib is arguably Novartis's closest competitor. It posted positive Phase 3 results and demonstrated noninferiority to ocrelizumab in primary progressive MS, putting it ahead in the filing race.
So the competitive picture looks like this: Merck is out, Sanofi has a liver problem, Roche is leading, and Novartis just showed up with strong efficacy data and a clean safety record. That's a pretty good position to be in.
Why Wall Street Is Paying Attention
Reuters described the remibrutinib results as boosting "blockbuster" hopes, and analyst commentary has pointed to potential peak sales of $3 billion.
The commercial logic is straightforward. MS affects roughly 3.1 million people worldwide, and relapsing forms make up the majority of cases. It's a chronic disease requiring long-term treatment, which means a drug that works well and is tolerable over many years can generate enormous, sustained revenue. The fact that remibrutinib is an oral pill (not an infusion) makes it even more attractive for both patients and insurers.
For Novartis specifically, the timing is strategic. The company has been rebuilding its pipeline through multiple deals, including the recent Avidity Biosciences acquisition that added neuromuscular disease programs. Remibrutinib sits in a different therapeutic bucket (immunology, not neurology), but it's part of the same growth story: diversify the portfolio and create new revenue streams before existing products face generic competition.
The Bigger Picture
The BTK inhibitor class has survived its adolescence. After evobrutinib's failure raised existential doubts and tolebrutinib's liver issues narrowed the field, the question has shifted from "can BTK inhibitors work in MS?" to "which one wins on risk versus benefit?"
Remibrutinib's answer so far is compelling: strong relapse reduction, meaningful disability delay, and no liver red flags in roughly 2,000 patients. Full data presentations (likely at a major neurology conference) will fill in the details that investors and neurologists need to see. But the early scorecard looks like Novartis has a real contender.
For the millions of MS patients managing their disease with imperfect options, the promise is simple: a drug that quiets the immune system without gutting it. Not a bouncer. A therapist.
4 min read
Merck Just Paid $400M for a Drug That Doesn't Exist Yet
Merck just dropped $400 million on a Chinese biotech's preclinical cancer drug targeting a protein scientists called "undruggable" for 40 years. The KRAS G12D race is on, and Merck's gamble says everything about where Big Pharma is shopping for its next blockbuster.
